Use of immunomodulating drugs and risk of cutaneous melanoma: A nationwide nested case-control study
Source: MDLinx, December 2020
Using the Cancer Registry of Norway, researchers assessed the links between use of immunomodulating drugs and risk of melanoma, at a nationwide population level.
They selected patients aged 18– 85 with a first primary cutaneous melanoma diagnosed in 2007– 2015 (n = 12,106).
Elevated risk of melanoma was observed in relation to use of ≥ 8 prescriptions of immunosuppressants vs ≤ 1 prescription.
